HNST Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
["Not a good buy right now for an impatient buyer: the stock remains in a clear downtrend (bearish MAs + weakening MACD), and there is no proprietary \u201cstrong buy\u201d signal to justify jumping in.", "Price is sitting right on first support (S1 2.378). A small oversold bounce is possible, but the trend still favors sellers until HNST reclaims the pivot (2.481) and holds above it.", "Options positioning is mixed (very call-heavy open interest but put-heavy daily volume), which reinforces \u201cwait for confirmation\u201d rather than buying immediately."]
["Intellectia Proprietary Trading Signals", "- AI Stock Picker: no signal on given stock today.", "- SwingMax: No signal on given stock recently.", "Trend/Momentum: MACD histogram is negative (-0.00501) and expanding bearishly \u2192 downside momentum is still building.", "Moving averages: SMA_200 > SMA_20 > SMA_5 \u2192 structurally bearish trend (rallies more likely to be sold).", "RSI(6) ~27.25 \u2192 oversold/washed-out conditions; this can trigger short-term bounces, but by itself is not a buy signal in a strong downtrend.", "Key levels: Support S1 ~2.378 (very close to current), then S2 ~2.314. Resistance: Pivot ~2.481, then R1 ~2.584. For a credible reversal, price needs to regain ~2.481 and push toward ~2.584."]
could support incremental demand/brand engagement in personal care.", "Pattern-based projection provided suggests potential for a stronger next-month move (+15.36% indicated), consistent with oversold rebound potential if the stock can hold support."]
["Competition pressure (notably diapers) and increased promotions flagged by JPMorgan \u2192 can weigh on revenue quality and margins.", "Transformation/exit of lower-margin categories may pressure reported results near-term and keep visibility low (multiple analysts highlight this).", "Current tape is risk-off (S&P 500 -0.52% today) and HNST\u2019s technical setup is already bearish, which can amplify weakness."]
["Latest quarter: 2025/Q3.", "Revenue: $92.57M, down -6.72% YoY \u2192 top-line contraction remains the main issue.", "Gross margin: 37.26%, down -3.70% YoY \u2192 profitability quality weakened even as the company restructures.", "Net income: $0.758M, up +359.39% YoY; EPS: $0.01 \u2192 improvement, but absolute earnings power remains small and sensitive to small operating changes."]
["Recent trend is clearly negative: multiple downgrades and broad price target cuts since Q3 results and \u201cTransformation 2.0.\u201d", "JPMorgan (2026-01-16): double downgraded to Underweight from Overweight (no PT) citing heightened competitive pressure and need for promotions; notes exit of lower-margin categories.", "Morgan Stanley (2025-11-19): Equal Weight maintained, PT cut to $3 from $4.25; cites weaker Q3 and low visibility.", "Lake Street (2025-11-06): downgraded to Hold from Buy; PT cut to $3 from $7; expects range-bound trading until consistent growth/margins improve.", "Some pros remain constructive but cautious (AGP/B. Riley kept Buy with reduced PTs), implying Wall Street \u2018pro\u2019 case hinges on execution of restructuring and eventual margin recovery; \u2018con\u2019 case is near-term revenue/margin pressure and competitive intensity.", "Influential/political trading check: no recent congress trading data available; hedge funds and insiders show neutral activity (no significant recent trends)."]
